BIT Capital GmbH Sells 20,957 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Key Points

• BIT Capital GmbH reduced its stake in IDEAYA Biosciences, Inc. by 32.9%, selling 20,957 shares and leaving them with 42,715 shares valued at approximately $700,000.
• Several institutional investors, such as Mariner LLC and PNC Financial Services Group, have increased their holdings in IDEAYA, indicating positive sentiment among large investors.
• Analysts have mixed ratings for IDEAYA, with three rating it as a hold and ten as a buy, while the consensus price target is set at $48.09.

BIT Capital GmbH lowered its position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 32.9% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 42,715 shares of the company's stock after selling 20,957 shares during the period. BIT Capital GmbH's holdings in IDEAYA Biosciences were worth $700,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Janus Henderson Group PLC grew its holdings in IDEAYA Biosciences by 13.5% during the 4th quarter. Janus Henderson Group PLC now owns 5,857,639 shares of the company's stock worth $150,606,000 after acquiring an additional 695,263 shares during the last quarter. Norges Bank bought a new stake in IDEAYA Biosciences during the 4th quarter worth approximately $13,385,000. MPM Bioimpact LLC bought a new stake in IDEAYA Biosciences during the 4th quarter worth approximately $10,641,000. FMR LLC grew its holdings in IDEAYA Biosciences by 2.6% during the 4th quarter. FMR LLC now owns 12,963,151 shares of the company's stock worth $333,153,000 after acquiring an additional 327,498 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in IDEAYA Biosciences by 5.9% during the 4th quarter. Vanguard Group Inc. now owns 5,078,084 shares of the company's stock worth $130,507,000 after acquiring an additional 282,936 shares during the last quarter. Institutional investors and hedge funds own 98.29% of the company's stock.

IDEAYA Biosciences Price Performance

Shares of IDYA stock traded up $0.09 on Tuesday, hitting $25.09. The stock had a trading volume of 225,419 shares, compared to its average volume of 1,155,064. The business has a 50 day moving average of $22.19 and a 200 day moving average of $20.33. The stock has a market cap of $2.20 billion, a price-to-earnings ratio of -6.98 and a beta of 0.09. IDEAYA Biosciences, Inc. has a 12-month low of $13.45 and a 12-month high of $40.74.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.03). During the same period last year, the firm posted ($0.68) EPS. The business's revenue for the quarter was up NaN% compared to the same quarter last year. As a group, research analysts expect that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the stock. The Goldman Sachs Group upgraded shares of IDEAYA Biosciences to a "hold" rating and set a $25.00 target price on the stock in a report on Thursday, July 10th. Wells Fargo & Company started coverage on shares of IDEAYA Biosciences in a research note on Thursday, June 26th. They issued an "overweight" rating and a $44.00 price objective for the company. Royal Bank Of Canada raised shares of IDEAYA Biosciences from an "outperform" rating to a "moderate buy" rating and cut their target price for the stock from $57.00 to $30.00 in a research note on Wednesday, July 9th. JPMorgan Chase & Co. increased their target price on shares of IDEAYA Biosciences from $66.00 to $72.00 and gave the stock an "overweight" rating in a research note on Monday, July 28th. Finally, TD Cowen started coverage on shares of IDEAYA Biosciences in a research note on Tuesday, July 22nd. They set a "buy" rating on the stock. Three analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $48.09.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.